Sugi Predict

Sugi Predict / Compounds / SCHEMBL16636780

SCHEMBL16636780

SCHEMBL16636780

COc1cc(C(=O)O)c([N+](=O)[O-])cc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 1/20 0.56
▸ FYN P06241 1/20 0.56
▸ PKM P14618 1/20 0.54
▸ LMNA P02545 3/20 0.47
▸ POLB P06746 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ MAPT P10636 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ TPMT P51580 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ DTYMK P23919 1/20 0.43
▸ EIF4E P06730 1/20 0.42
▸ CASP3 P42574 1/20 0.42
▸ SENP8 Q96LD8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22324330 1.00 LCK (0.56) LCKFYNPKMLMNAPOLB
SCHEMBL2903458 0.89 PKM (0.58) LCKFYNPKMLMNAPOLB
SCHEMBL14915504 0.88 LCK (0.65) LCKFYNPKMLMNAPOLB
SCHEMBL31549975 0.87 PKM (0.59) LCKFYNPKMLMNAPOLB
SCHEMBL375897 0.87 PKM (0.59) LCKFYNPKMLMNAPOLB
SCHEMBL15972175 0.86 POLB (0.51) PKMLMNAPOLBHTTMAPT
Methyl Alcohol SCHEMBL27781670 0.85 PKM (0.58) LCKFYNPKMLMNAPOLB
SCHEMBL28454415 0.85 PKM (0.58) LCKFYNPKMLMNAPOLB
SCHEMBL22324347 0.84 POLB (0.53) PKMLMNAPOLBHTTMAPT
SCHEMBL26631818 0.83 TTR (0.48) LCKFYNPKMLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
WO-2025227148-A1 BICYCLIC HETEROCYCLE COMPOUNDS FOR TREATMENT OF HERPES VIRUSES ASSEMBLY BIOSCIENCES, INC. (US) 2025-10-30 — — WO disclosed
WO-2025109474-A1 SUBSTITUTED IMIDAZOARENES AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-05-30 — — WO disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
CN-112110918-B Spiro substituted pyrimido cyclic compounds, process for their preparation and their use in medicine 劲方医药科技(上海)有限公司 2023-08-22 — — CN disclosed
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2018-05-03 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
US-9840516-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2017-12-12 — — US disclosed
EP-3055290-A1 INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-08-17 — — EP disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LCK 1421/4885FYN 2167/4885PKM 3088/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 LCK 4045/4885FYN 3117/4885PKM 3678/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS LCK 2424/4885FYN 3024/4885PKM 2869/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LCK 2424/4885FYN 3024/4885PKM 2869/4885
US-20180118757-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LCK 2424/4885FYN 3024/4885PKM 2869/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LCK 2641/4885FYN 2270/4885PKM 3104/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LCK 2641/4885FYN 2270/4885PKM 3104/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS LCK 2641/4885FYN 2270/4885PKM 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.